Drug Patents owned by Tetraphase Pharms

1. List of Xerava drug patents

XERAVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Aug, 2029

(6 years from now)

US8906887 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2023
Generating Antibiotic Incentives Now (GAIN) Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-08-28

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

XERAVA family patents

15

United States

5

Japan

4

Korea, Republic of

4

China

4

European Union

3

Israel

3

Hong Kong

3

Argentina

3

Spain

3

Poland

3

Taiwan, Province of China

3

New Zealand

2

Denmark

2

Mexico

2

Slovenia

2

Hungary

2

Singapore

2

Croatia

2

Portugal

2

Cyprus

2

RS

1

Australia

1

Lithuania

1

Morocco

1

Philippines

1

Norway

1

Colombia

1

Brazil

1

Netherlands

1

San Marino

1

Luxembourg

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in